Please login to the form below
outcomes
This page shows the latest outcomes news and features for those working in and with pharma, biotech and healthcare.
Roche engaged in talks with FDA for Alzheimer’s drug candidate
I wouldn’t be able to speculate what the outcome of this dialogue will be”. ... comprehensive trial so, whatever the outcome of this trial will be, we will have a definitive answer of what we can do for patients with this terrible disease so let's
Latest news
-
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
In June, Merck and Eisai also announced that the Keytruda plus Lenvima combination treatment improved outcomes when compared to Pfizer’s Sutent (sunitinib) on a measure of health-related quality of
-
FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
The CRDAC outcome is not surprising, after briefing documents published ahead of the committee meeting earlier this week raised questions over the safety profile of roxadustat for the treatment of anaemia ... Although we are disappointed by today’s
-
Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
Lilly later reported that although secondary outcomes within this trial ‘showed no substantial difference’, exploratory analyses showed donanemab slowed the accumulation of tau across key brain regions in Alzheimer’s patients.
-
MHRA outlines two-year delivery plan with ‘patient first’ focus
direct action to support and protect patients and improve health outcomes,” she added.
-
Q&A: Claire Gillis
What’s the best thing about working in healthcare comms? The opportunity to influence outcomes for patients – whether through a new approval, better reimbursement or making sure doctors understand why an ... A great orator who packaged information
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
Lilly and Banner Alzheimer’s Institute collaborate on donanemab prevention trial
MHRA outlines two-year delivery plan with ‘patient first’ focus
Q&A: Claire Gillis
More from news
Approximately 14 fully matching, plus 1,884 partially matching documents found.
Latest Intelligence
-
The future of work has been just around the corner for some time...
Critically, we need to keep sight of the key components that form the PERMA model where flow also has a home (Seligman, 2012), where ‘flourishing’ is our desired outcome, which will ... Our challenge is to consistently check that the melting pot of
-
Paving the way for the HCP omnichannel experience: a guide for medical affairs
In summary, medical affairs is ideally positioned to optimise communication experiences for HCPs by embracing an OC engagement approach that will lead to improved patient outcomes.
-
Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
Understanding those conversations can provide early intelligence on the most likely outcomes during policymaker discussions, and can even provide pharmaceutical companies with evidence to shape their applications in order to achieve ... a more favourable
-
Pharma’s authentic proof of purpose influences decisions among HCPs and payers
Physicians, the closest to direct patient care, were most likely to associate their own purpose with achieving the best individual patient outcomes.
-
The love/hate relationship between creativity and data in healthcare
And nowhere is that constraint more abundant than in healthcare. It comes from business strategies, market access landscapes, regulatory bodies, focus groups, patient outcomes and even market research studies – all of
The future of work has been just around the corner for some time...
Paving the way for the HCP omnichannel experience: a guide for medical affairs
Pre-launch planning and DSLs – the new ways to create launch excellence in pharma
Pharma’s authentic proof of purpose influences decisions among HCPs and payers
The love/hate relationship between creativity and data in healthcare
More from intelligence
Approximately 10 fully matching, plus 540 partially matching documents found.
Latest appointments
-
Ashfield Engage appoints Serap Becker as head of patient solutions in DACH region
Serap joins us at an exciting time for Ashfield Engage, as the demand for patient engagement programmes propels across the industry to support patients, improve adherence and achieve better outcomes,” said
-
Paula Hensler joins Havas Just:: as scientific director
The focus for pharma is on demonstrating commitment to improving patient outcomes and developing programmes which create confidence among multiple stakeholders.
-
Lucid Group promotes Clare Reynolds to newly created role
In her new role, Reynolds will aim to enhance Lucid's ability to improve health outcomes and also build on the company's strategic partnerships. ... By firmly engaging with this intent through our client partnerships, we lead with improving patient
-
Havas Health & You appoints Pat Thistlethwaite as chief experience officer
improving the lives and health outcomes of people around the world.”.
-
New faces at Synergy Vision, Makara Health and JPA Health
I’m passionate about delivering projects that challenge the status quo and improve patient outcomes, so this is an incredibly exciting time to be at the forefront of medical communications with
Ashfield Engage appoints Serap Becker as head of patient solutions in DACH region
Paula Hensler joins Havas Just:: as scientific director
Lucid Group promotes Clare Reynolds to newly created role
Havas Health & You appoints Pat Thistlethwaite as chief experience officer
New faces at Synergy Vision, Makara Health and JPA Health
More from appointments
Approximately 0 fully matching, plus 68 partially matching documents found.
Latest from PMHub
-
Employee wellbeing in creative agencies: three tips to get you started
When we work together our outcome is far greater than the sum of the parts.
-
Eoin McAtamney announced as Managing Director of Ashfield Ireland
ssible outcomes, as well as the operational sensitivities in the current market.
-
Ashfield to host webinar on Patient Support Programmes on Tuesday 10 October
Pharma’s ambition is to deliver a truly differentiated service with measurable results and improved patient outcomes.
-
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
21. Discrepancy in health outcomes for communities of different ethnicities and socioeconomic backgrounds.
-
MSL Digital Offices and HCP Community Boards: A Customer Story
To learn more about our client’s approach and the outcomes of this project, access the full customer story here.
WHITE PAPER: From bench to bedside in one year - how the race for a COVID-19 vaccine will change the future of drug development
More from PMHub
Approximately 9 fully matching, plus 604 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Digital strategist
-
Competitive
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital account director
-
Competitive
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- Another Landmark Lucid Workiversary
- Amgen pays $900m upfront to acquire Teneobio’s antibody assets, R&D technologies
- Biogen and Eisai present new data for controversial Alzheimer's drug Aduhelm at AAIC
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Recruiting patients for real-world studies – the power of a digital campaign
- EU approves bluebird bio’s CALD gene therapy Skysona
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- FDA advisory committee votes against approval of AZ, FibroGen's roxadustat
- This month in 1939: How dead cattle led to the discovery of warfarin
- Recruiting patients for real-world studies – the power of a digital campaign
PMHub
ROAD
ROAD is a digital PR and communications consultancy specialising in promoting the innovators that shape our future health and wellbeing....
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
